Monday May 21, 7:31 am Eastern Time
Press Release
Duramed's UBS Warburg Presentation Available via Telephone Conference
CINCINNATI--(BW HealthWire)--May 21, 2001--Duramed Pharmaceuticals, Inc. (Nasdaq:DRMD - news) announced today that the audio portion of its presentation at the UBS Warburg Global Specialty Pharmaceuticals Conference at 11:30 a.m. EDT on May 22, 2001, will be available live for public access by calling (719) 457-2605 or (888) 515-2781.
A recording of the presentation will be available for four weeks after the conference by calling (402) 220-8537 or (800) 759-8603.
Presenting at the conference with be E. Thomas Arington, Duramed's chairman and chief executive officer, and Kathi Rinesmith, the company's vice president of research and development.
About Duramed Pharmaceuticals, Inc.
Duramed Pharmaceuticals develops, manufactures and markets prescription drug products. The company's business strategy emphasizes products with attractive market opportunities and potentially limited competition due to technological barriers to entry, focusing on women's health and the hormone replacement therapy market. The company's mission is to be the premier supplier of solid oral dose hormone products.
Duramed's containment manufacturing facility for the production of hormones distinguishes the company from most competitors. The facility incorporates enclosed product flow and state-of-the-art environmental controls to ensure purity, stability, and tablet uniformity for its hormone products.
The company's stock is traded on Nasdaq using the symbol DRMD. Additional information about the company can be found on the World Wide Web at www.duramed.com and www.cenestin.com.
--------------------------------------------------------------------------------
Contact:
Duramed Pharmaceuticals, Inc.
INVESTOR AND MEDIA INQUIRIES: 513/731-9900
www.duramed.com
or
In-Site Communications, Inc.
INVESTOR RELATIONS:
Lisa Carlton-Wilson, President, 212/759-3929 |
